Sai Life Sciences Ltd: Leveraging Chemistry for Accelerated BioPharma Drug Discovery
From its inception, SAI has prioritized the development of core capabilities in chemistry.
From its inception, SAI has prioritized the development of core capabilities in chemistry.
FDA feedback indicates that Precision Biosciences’Â shared CMC plans are compliant with Agency expectations.
With 146 billion won, Daewoong Bio intends to enter the contract development and manufacturing organization (CDMO) market.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings